Sanyou Biopharmaceuticals Completes Series B Financing to Accelerate Construction of Integrated R&D Service Platform for Innovative Antibody Drugs

VCBeat learned at the earliest opportunity,Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as “Sanyou Biopharmaceuticals” or the “Company”), an innovative antibody drug discovery company, announced the completion of its Series B financing.This round of financing was co-led by Linghang Xinjie Capital and Motianshi Investment, with Huiyuan Capital and existing shareholder Suizhen Investment participating as co-investors. Mr. Lan Zhiyin, Investment Partner at Linghang Xinjie, joined the Board of Directors of Sanyou Biopharmaceuticals following the closing of this transaction. Prior to this, Sanyou Biopharmaceuticals had completed its Series A financing in May 2020, jointly invested by Haier Medical and Zhijiang Biology.

Sanyou Biopharmaceuticals, established in 2015, focuses on the research and development of innovative antibody drugs. Guided by the vision of “enhancing people’s quality of life through innovative antibody therapeutics” and the mission of “making the development of innovative antibody drugs accessible to all,” the company continues to build a globally leading high-throughput, integrated R&D platform for innovative antibody drugs. It has accumulated and developed extensive technical resources, including the world’s largest antibody library. Sanyou Biopharmaceuticals not only provides cutting-edge services but also works closely with partners to accelerate the development of innovative antibody therapies urgently needed by patients.

After six years of sustained and in-depth development, Sanyou Biopharmaceuticals has established an advanced and comprehensive integrated R&D platform for innovative antibody drug discovery. The company has provided hundreds of distinctive, packaged R&D services and phase-specific technical services for innovative antibody drug discovery projects to more than 150 pharmaceutical companies and drug R&D institutions worldwide, and has engaged in collaborative R&D on over 10 projects with more than 10 global partners.

Dr. Lang Guojun, CEO of Sanyou BiopharmaceuticalsHe stated, “We extend our sincere gratitude to both new and existing investors for their recognition and support of the company. Sanyou Biopharmaceuticals will fully leverage this round of financing to expand its R&D and service teams, accelerate the launch of a series of trillion-scale antibody libraries, and build an internationally leading, integrated R&D service platform for innovative antibody drugs characterized by a highly efficient combination of ‘modularity, automation, and integration.’ This initiative aims to thoroughly resolve the critical shortage of top-tier innovative antibody drug candidate molecules—often described as ‘a general hard to find’—and seamlessly connect all stages from ‘target identification to IND (Investigational New Drug) application.’ By doing so, we enable all companies and individuals committed to innovative antibody drug development to fully utilize Sanyou’s open platform and realize their dreams of developing new drugs.”

Lan Zhiyin, Investment Partner at Linghang Xinjie, stated: “Linghang Xinjie adheres to long-term value investment, actively promotes the innovation and growth of Chinese enterprises, and drives industrial progress and development. Sanyou Biopharmaceuticals has been deeply engaged in the field of antibody drug discovery for many years, establishing a comprehensive integrated R&D platform for innovative antibody drugs and possessing leading capabilities in innovative antibody drug discovery. We are delighted to participate in this round of investment to support Sanyou Biopharmaceuticals in building an internationally leading R&D service platform for innovative antibody drugs.”

Zeng Yinghua, Head of Investment at Motian Stone Capital, stated: “Motian Stone has long focused on frontier advancements in the field of innovative antibody drugs. Sanyou Biopharmaceuticals specializes in R&D services for innovative antibody drugs, implementing a dual business mechanism of service provision and collaborative R&D. We highly recognize the technical capabilities and execution efficiency of the Sanyou team, and we believe that Sanyou Biopharmaceuticals can assist Chinese pharmaceutical companies in advancing drug development in China.”

Zhang Shanshan, President of Huiyuan Capital, stated, “Innovative antibody drugs represent one of the fastest-growing sectors in biopharmaceuticals and hold significant long-term investment value. Sanyou Biopharmaceuticals has been deeply engaged in the R&D and services of innovative antibody drugs for many years, possessing internationally leading integrated antibody drug development capabilities while continuously strengthening its own R&D platform construction. We highly recognize the focus and execution capability of Sanyou Biopharmaceuticals’ management team. As an investor in this round, we will work together to help Sanyou achieve continuous breakthroughs and reach more milestones. We are confident that the company will bring substantial empowerment and contributions to the entire antibody drug R&D industry.”

Weng Cui, Partner at Zhuzhen Holdings, stated, “As the equity investment arm of Zhuzhen Holdings, Suizhen Investment has maintained a long-term bullish outlook on the broad field of new drug R&D and has participated in three rounds of additional investment in Sanyou Biopharmaceuticals. As an early shareholder of Sanyou Biopharmaceuticals, we have consistently recognized the innovative spirit and strategic decision-making of its core team in the field of antibody drug development, and have witnessed the company’s rapid growth. We will continue to provide steadfast, long-term support for the development of Sanyou Biopharmaceuticals, looking forward to its platform and technologies delivering new breakthroughs in the R&D of innovative antibody drugs.”

Linghang Xinjie Capital was established in 2018. Its founding team boasts extensive experience and international standards, specializing in empowerment-oriented investment. By focusing professionally on the two major sectors of intelligent technology and biomedicine, and leveraging the comprehensive layout of professional incubators, USD funds, and RMB funds within the Linghang ecosystem, it has created a competitive and differentiated VC innovation model with remarkable investment achievements. Many of its portfolio companies have successfully listed on the A-share market and NASDAQ, with internal rate of return (IRR) ranking among the top in the industry. Meanwhile, Linghang Xinjie is also a capital-industry company deeply engaged in value creation. Adhering to long-term value investment and operating across China and the United States, it utilizes capital as a means to achieve industrial integration, actively promoting the innovation and growth of Chinese enterprises and driving industrial progress and development. Linghang Xinjie collaborates with investors to provide strong support for entrepreneurs, jointly building world-class companies.

Motonstone Investment Holdings Co., Ltd., established in December 2009, is the equity investment platform under Guangdong Guangrun Group Co., Ltd. It primarily invests in entrepreneurial and innovative projects across various sectors, including pharmaceuticals, big health, artificial intelligence, and semiconductors, covering venture capital (VC), industrial investment, and private equity (PE) investment. As an integral component of the Group’s industrial ecosystem, Guangrun Group owns multiple pharmaceutical manufacturing enterprises, health supplement companies, venture capital firms, and industrial incubation bases. Its pharmaceutical subsidiary, controlled by the Group and engaged in production and R&D, was successfully listed on the ChiNext Board in 2017.

Huiyuan Capital, established in 2019 as a joint venture between a professional investment team and state-owned capital, is an emerging medical investment firm dedicated to long-term investments in the biopharmaceutical and medical device sectors. It systematically targets high-quality companies with breakthrough and innovative technologies within niche sub-sectors. By forging deep collaborative partnerships with multiple industry players and adhering to an investment strategy of “industry empowerment + capital support,” Huiyuan Capital aims to deliver sustained and stable investment returns to its investors.

Suozhen Investment is the equity investment business segment of Shanghai Zhuzhen Investment Holding Co., Ltd. (“Zhuzhen Holding”). Established in 2017, the company serves as a key investment platform with participation from Zhejiang University. Its shareholders consist entirely of Zhejiang University alumni and affiliated enterprises, including Insigma Technology, Zhejiang University Holdings (Zhejiang University Youchuang), actual controllers of multiple listed companies, as well as seasoned investment experts, internet entrepreneurship elites, and other prominent public figures. Embracing an entrepreneurial mindset of “always on the journey” and upholding the “Qiushi Spirit” (the spirit of seeking truth), the company integrates global alumni resources. Through platform operations, it fosters collaboration among alumni and between alumni and their alma mater, facilitating the integration of industry and finance. By consolidating innovation and entrepreneurship resources, it provides robust momentum for the development of outstanding enterprises through open cooperation. Furthermore, it promotes industrial transformation and upgrading via market-oriented operations, striving to achieve win-win outcomes for all stakeholders.

Sanyou Biopharmaceuticals is an internationally leading, high-tech biotechnology enterprise dedicated to the research, development, and services of innovative antibody-based therapeutics. The company is committed to building a world-class, integrated platform for high-quality, high-throughput R&D and value translation of innovative antibody drugs, while establishing a business ecosystem encompassing therapeutic, R&D, and diagnostic products and services. By collaborating with global biopharmaceutical, diagnostic, and drug development companies, Sanyou Biopharmaceuticals aims to pioneer new frontiers in the diagnosis and treatment of human diseases.

Since its establishment, the company has maintained rapid development. As of May 2021, the company had a professional team of more than 160 members, with over 70% holding doctoral or master’s degrees. The team possesses comprehensive experience in the R&D and industrialization of innovative drugs. The company has established an integrated R&D laboratory for innovative antibody-based therapeutics spanning thousands of square meters within the Shanghai Caohejing National Hi-Tech Park, equipped with advanced facilities. It features ten major functional modules and more than 40 core technology platforms, represented by its series of ultra-large phage display antibody libraries (each exceeding 10^11 diversity), covering innovative antibody drug discovery, antibody engineering, in vitro and in vivo efficacy screening, developability assessment of antibody drugs, construction of production cell lines, and process development.

The company continuously introduces new technologies, products, services, and scenarios that offer “the best quality, the fastest speed, and the highest cost-effectiveness.” It has established friendly business partnerships with more than 150 pharmaceutical companies, drug R&D institutions, and diagnostic reagent product development firms worldwide.

Excellence in Innovation, Pursuit of Dreams, Relentless Effort, and Benefit to Patients! Sanyou Biopharmaceuticals looks forward to working with our extensive customer base and partners to jointly build a long-term, synergistic growth ecosystem and contribute to a healthier society.

The following is the English version:

Headline:  Sanyou Biopharmaceuticals completes series B financing and secures its leading role in innovative antibody drug discovery 

On June 26, 2021, Shanghai: Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereafter referred to as "Sanyou Bio" or "the Company"), a leading company in innovative antibody drug discovery, announced the closing of series B financing. This financing round was co-led by LH Ventures and Montesy Investment, and followed by Grand Mount Capital and Seeking Capital (an existing investor). After this round of financing, Zhiyin Lan, venture partner of LH Ventures, will join the Board of Directors of Sanyou Bio. Previously, Sanyou Bio obtained joint series-A funding from Haier Biomedical and Shanghai Liferiver Bio-Tech in May 2020.

Established in 2015, Sanyou Bio focuses on R&D of innovative antibody drugs. The Company’s vision is to improve quality of life with innovative antibody drugs, and their mission is to empower the industry to develop any innovative antibody drug. Sanyou Bio have been continuously building a world-leading high-throughput integrated R&D platform for innovative antibody drugs, collecting technical resources to establish the largest antibody library in the world. While providing leading services, Sanyou Bio have made every effort to collaborate with their partners to develop innovative antibody drugs to meet the patients’ need.

After 6 years of persistent endeavor, Sanyou Bio has established a state-of-the-art integrated R&D platform for innovative antibody drug discovery, provided hundreds of unique R&D solutions and technical services for innovative antibody drug discovery projects to more than 150 pharmaceutical companies and drug development institutions around the world, and carried out more than 10 collaborative R&D projects with more than 10 partners.

Dr. David (Guojun) Lang, CEO of Sanyou Bio, stated, "we are very grateful to our previous and new investors for their recognition and support. We will make the best use of this funding round to expand our R&D and service teams, expedite the launching process of a number of super-trillion antibody libraries, and build a world-leading modular, automated, and integrated innovative antibody drug integrated R&D service platform to overcome the difficulty of finding top-notch candidate molecules of innovative antibody drugs and clear the path from a target selection to IND application. We hope that all companies and individuals aspired to R&D of innovative antibody drugs can leverage fully with Sanyou Bio's open platform to achieve their pursuit of new drug development."

Zhiyin Lan, venture partner of LH Ventures, stated, "LH Ventures commits to long-term value investment, actively promotes the innovation and growth of Chinese enterprises, and promotes industrial progresses and development. Sanyou Bio has devoted in antibody drug discovery for years, and established a comprehensive integrated R&D platform and equipped with leading competence in innovative antibody drug discovery. We are very excited to join this round of investment to assist Sanyou Bio in building a world-leading R&D service platform for innovative antibody drugs."

Yinghua Zeng, chief investment officer of Montesy Investment stated, " Montesy has focused on forefront progresses in the area of innovative antibody drugs for a long time. Sanyou Bio focuses on R&D services of innovative antibody drugs and implements dual business patterns of services plus collaborative R&D. We highly recognize the technical competence and execution efficiency of Sanyou Bio's team. We believe that Sanyou Bio can assist Chinese pharmaceutical industry and promote drug development in China."

Shanshan Zhang, president of Grand Mount Capital, stated, "Innovative antibody drugs are one of the fastest growing sectors in biopharmaceutical industry, and have long-term investment values. Sanyou Bio has devoted in innovative antibody drug R&D and services for years, has world-leading technical competence in integrated antibody drug R&D, and has been continuously strengthening the construction of its own R&D platform. We highly recognize the dedication and execution capability of Sanyou Bio's management team. As one of the investors of this funding round, we will assist Sanyou Bio for its continuous breakthrough to reach more milestones. We believe that the Company will bring huge empowerment and contribution to the whole industry of antibody drug R&D."

Cui Weng, partner of Seeking Capital, stated, "Seeking Capital has strong confidence in new drug R&D in the long-term, that’s why we have invested in Sanyou Bio for three rounds. As one of the early shareholders, we have always appreciated the innovation and strategies of Sanyou Bio's core team in the antibody drug R&D field and we have witnessed its rapid growth since 2018. We will continue to firmly support the future development of Sanyou Bio and look forward to seeing Sanyou Bio's platform and technologies bringing new breakthroughs in the near future."

LH Ventures was established in 2018. The founding team has rich experience and world class skills in enabling investment. With its professional dedication to intelligent technologies and biomedical sectors, and reliance on the full layout of its ecosystem including professional incubators, USD funds and RMB funds, LH Ventures has built a competitive and differentiated VC innovation mode and achieved striking investment achievements. Several enterprises LH Ventures invested have been successfully listed in China A share and Nasdaq, with the highest IRRs ranking in the industry. Moreover, LH Ventures is also a capital investment company deeply involved in value creation. LH Ventures commits to long-term value investment across China and the United States, and has accomplished industry integration with capital, actively promoted innovation and growth of Chinese enterprises, and drove industrial progresses and development. Along with other investors, LH Ventures provides powerful support to entrepreneurs to build world-class companies together. 

Established in December 2009, Montesy Investment Holding Co., Ltd. (Montesy Investment) is an equity investment platform under Guangdong Guangrun Group Co., Ltd. (hereafter referred to as Guangrun Group), mainly investing in entrepreneurship projects and innovation projects in fields including pharmaceuticals, big health industry, artificial intelligence, and integrated circuit. It’s business covers VC, industrial investment, and PE investment, and is an important part of the Group’s industrial ecosystem. Guangrun Group owns many pharmaceutical enterprises, nutraceutical enterprises, venture capital (VC) companies, and industrial incubation bases. A subsidiary of Guangrun Group specialized in pharmaceutical manufacture and R&D successfully went IPO in China Growth Enterprise Market in 2017.

Grand Mount Capital (GMC) is a dedicated healthcare venture capital firm established by state-owned capital and investment professionals in 2019. GMC’s investment spans biopharmaceuticals, medical devices, and diagnostics. Adhering to the strategy of “Industry participation+capital assistance", GMC works closely with multiple healthcare conglomerates to add value to portfolio companies by providing active support in market access, collaborations, regulatory guidance, etc. GMC aims to deliver long-term and sustainable return for investors while becoming a trusted partner to entrepreneurs that aim to build great companies with breakthrough technologies.

Established in 2017, Shanghai Seeking Capital Holding Co., Ltd. (Seeking Capital) is an innovative investment platform founded by Zhejiang University’s alumni. Its shareholders include Zhejiang University’s affiliated enterprises such as Insigma Group and Future Capital, CEOs of listed companies, investment professionals, industry experts and elite entrepreneurs. With "faith-of-truth spirit" entrepreneurial mindset, Seeking Capital embraces to integrate global resources of Zhejiang University, its alumni and beyond. Its investment portfolio mainly focuses on life science and healthcare, IT, and intelligent manufacturing industries. Through Seeking Capital’s integrative platform, it enables collaboration between the alumni and the alma mater, and assists in industry-finance integration. Seeking Capital further fuses innovation and entrepreneurship resources to provide surging power to start-up enterprises, drives industrial transformation and upgrading, and strives to achieve a win-win situation for multiple parties.

Sanyou Biopharmaceuticals Co., Ltd. is a leading international biological high-tech enterprise focusing on R&D and services of innovative antibody drugs.

The company is committed to establishing a leading high-quality, high-throughput, and integrated R&D and value transformation platform for innovative antibody drugs internationally, constructing a business ecosystem involving therapy, R&D, and diagnostic products and services, and cooperating with global biopharmaceutical, diagnostic, and drug R&D companies to make a new progress in the diagnosis and treatment of human diseases.

Since its establishment 6 years ago, Sanyou Bio has maintained rapid development. As of May 2021, the company has more than 160 members in a professional team, of which the proportion of doctors and masters is more than 70%. The team has full experience in innovative drug development and industrialization. Sanyou Bio has established an integrated innovative antibody drug R&D laboratory of several thousand square meters with advanced facilities in "Shanghai Caohejing Hi-Tech Park". There are 10 major functional modules and more than 40 core technological platforms which are characterized by a series of sub-Trillion phage display antibody libraries, covering innovative antibody drug discovery, antibody engineering, in vitro and in vivo efficacy screening, antibody drug developability analysis, construction of cell lines for production, and manufacturing process development, etc.

The company is continuing to launch new technologies, new products, new services, and new scenarios of "the best quality, the fastest speed, and the highest cost performance". Friendly business cooperation relations have been established by the company with more than 150 pharmaceutical companies, drug R&D institutions, and diagnostic reagent and product development companies worldwide.

Excellence and innovation, pursuit of dreams, striving and envolving, for the benefit of patients! Sanyou Bio looks forward to jointly building a long-term collaborative growth ecosystem and a healthy society with our clients and partners.